A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
by on Friday, August 17th, 2012 | No Comments
Condition: Malignant Melanoma
Interventions: Drug: vemurafenib; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting – verified August 2012
Follow this link: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma